Skip to main content
Figure 3 | Journal of Experimental & Clinical Cancer Research

Figure 3

From: Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin

Figure 3

Inhibition of angiogenesis within tumor estimated by CD31 immunohistochemical analysis. (A) were representative sections from each group. a: Ad-hEndo+ cisplatin; b: Ad-hEndo; c: cisplatin; d: Ad-null; e: NS. (B) Vessel density was determined via counting the number of the microvessels per high-power field within hot spot area. Values were expressed as means ± SE (5 high power fields/slide). Tumors of the combination group showed smaller number of microvessel count than that of the other groups submitted to cisplatin or Ad-Endo alone, especially the NS (P < 0.05). a: Ad-hEndo+cisplatin; b: Ad-hEndo; c: cisplatin; d: Ad-null; e: NS.

Back to article page